890MO Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL
Eleni Tholouli(Manchester Royal Infirmary), K. Ardesha(University College London), R. Chen(Autolus (United Kingdom)), Maud Jonnaert(Autolus (United Kingdom)), Nancy L Bartlet(Washington University in St. Louis), A. Ramakrishnan, Simon Thomas(Autolus (United Kingdom)), Wendy Osborne(Newcastle upon Tyne Hospitals NHS Foundation Trust), Maria A. V. Marzolini(The London College), Y. Zhang(Autolus (United Kingdom)), Muhammad Al‐Hajj(GlaxoSmithKline (United States)), Nushmia Z. Khokhar(Autolus (United Kingdom)), Peter A. McSweeney(Mesoblast (United States)), Vijay Peddareddigari(Autolus (United Kingdom)), Martin Pulé(Autolus (United Kingdom)), David Irvine(NHS Greater Glasgow and Clyde), Carlos Bachier
Cited by 4
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k